Profile data is unavailable for this security.
About the company
X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
- Revenue in ILS (TTM)1.40m
- Net income in ILS-69.35m
- Incorporated1993
- Employees0.00
- LocationX T L Biopharmaceuticals Ltd5 Badner St.,P.O.Box 8241RAMAT GAN 5218102IsraelISR
- Phone+972 99557080
- Fax+972 99519708
- Websitehttps://www.xtlbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purple Biotech Ltd | 0.00 | -10.02m | 18.58m | 9.00 | -- | 0.1788 | -- | -- | -0.0158 | -0.0158 | 0.00 | 0.0559 | 0.00 | -- | -- | 0.00 | -8.80 | -34.27 | -10.44 | -37.87 | -- | -- | -- | -- | -- | -- | 0.0077 | -- | -- | -- | 63.58 | -- | -- | -- |
| X T L Biopharmaceuticals Ltd | 1.40m | -69.35m | 26.44m | 0.00 | -- | 0.2196 | -- | 18.89 | -0.3149 | -0.3149 | 0.0064 | 0.1272 | 0.0192 | -- | 0.7012 | 42,422.86 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
| Merchavia Holdings and Investments Ltd | 455.00k | -16.51m | 38.85m | 90.00 | -- | 1.73 | -- | 85.39 | -0.9269 | -0.9269 | 0.0251 | 1.07 | 0.017 | -- | 2.32 | 5,055.56 | -61.87 | -9.41 | -65.61 | -9.67 | -- | -- | -3,628.57 | -468.97 | -- | -0.1069 | 0.00 | -- | 307.39 | 4.24 | 57.04 | -- | -- | -- |
| BioLine RX Ltd | 39.27m | -9.18m | 39.16m | 28.00 | -- | 0.6502 | -- | 0.9973 | -0.0067 | -0.0067 | 0.0185 | 0.0231 | 0.2752 | 2.19 | 7.05 | 1,402,487.00 | -6.43 | -48.18 | -11.04 | -63.37 | 50.69 | -- | -23.38 | -450.09 | 1.93 | -2.59 | 0.3681 | -- | 502.92 | -- | 84.79 | -- | -5.85 | -- |
| Nextage Therapeutics Ltd | 413.00k | -3.28m | 63.15m | -- | -- | -- | -- | 152.90 | -0.0998 | -0.0998 | 0.0126 | -0.1637 | 0.5704 | -- | 2.76 | -- | -479.28 | -265.82 | -- | -- | 18.40 | 22.53 | -840.19 | -2,390.64 | -- | -110.94 | -- | -- | -52.85 | 6.82 | 15.36 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Ayalon Mutual Funds Ltd.as of 30 Nov 2025 | 489.37k | 0.05% |
